Human immunodeficiency virus (HIV)-specific T cells play a critical role in anti-virus immunity. Therefore, during the clinical development of immune-based
therapies, it is important to perform a diagnostic test that rapidly quantifies and characterizes cellular immune responses. For detection of functional HIV-specific CD8(+) cytotoxic T cells (CTL), we used a rapid
vaccinia assay that employs recombinant vaccinia virus-infected peripheral blood mononuclear cells (PBMC). This assay was compared with the traditional 51Cr-release CTL assay and with the
peptide pool-based
enzyme-linked immunospot assay (ELISPOT). We demonstrated a close correlation between these assays by using identical
antigens in parallel assays. However, the
vaccinia assay was the least expensive and time- and labor-consuming test. Regarding sensitivity, the
vaccinia assay was similar to both the
peptide pool-based ELISPOT and CTL assays. We showed that human histocompatibility leukocyte
antigen (
HLA)-Dr(+) cells are responsible for presenting recombinant
vaccinia antigens to T cells. The recombinant
vaccinia-based assay is a rapid, sensitive and quantitative test and is thus suitable for the detection of functional
antigen-specific CD8(+) CTL in large-scale clinical studies.